智通财经网·2026-01-23 10:41Core Viewpoint - China Resources Pharmaceutical (华润医药) reported a revenue of RMB 4.22 billion for Jiangzhong Pharmaceutical in 2025, reflecting a year-on-year decline of 4.87%, while the net profit attributable to shareholders increased by 14.96% to RMB 906 million [1] Group 1: Financial Performance - Jiangzhong Pharmaceutical achieved a revenue of RMB 4.22 billion in 2025, down 4.87% compared to the previous year [1] - The net profit attributable to shareholders reached RMB 906 million, marking a year-on-year increase of 14.96% [1] Group 2: Strategic Initiatives - The company is focusing on strengthening brand development amidst structural adjustments in the industry [1] - Jiangzhong Pharmaceutical is enhancing its marketing strategies, optimizing cost structures, and deepening lean manufacturing practices to improve profitability [1]